Mirabegron: new treatment for OAB with fewer side-effects

    loading  Checking for direct PDF access through Ovid

Abstract

Mirabegron (Betmiga) is a new class of drug for the treatment of overactive bladder. In our New products review, Steve Chaplin presents the clinical data relating to its efficacy and adverse events, and Professor Chapple discusses its place in treatment compared with anticholinergics.

Related Topics

    loading  Loading Related Articles